Acceleration of amyloidosis by inflammation in the amyloid-beta marmoset monkey model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 55, Issue 1, 2016, Pages 101-113

  Philippens, Ingrid H ^a   Ormel, Paul R ^a   Baarends, Guus ^a   Johansson, Maja ^b   Remarque, Ed J ^a   Doverskog, Magnus ^b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; amyloid; amyloidosis; inflammation; marmoset; microglia; non human primates; pathology; plaque progression; pro inflammatory cytokines

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-43]; BIOLOGICAL MARKER; CD45RA ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; LIPOPOLYSACCHARIDE; PHOSPHATE BUFFERED SALINE; PROTEIN IBA1; UNCLASSIFIED DRUG; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 6;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOGENESIS; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALLITHRIX JACCHUS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; IMMUNITY; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MIDDLE AGED; MONKEY MODEL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RIGHT HEMISPHERE; SENILE PLAQUE; WASTING SYNDROME; ANIMAL; BLOOD; BRAIN CORTEX; CALLITHRIX; CHRONIC WASTING DISEASE; DIAGNOSTIC IMAGING; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; PATHOPHYSIOLOGY; PILOT STUDY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; BIOMARKERS; CALLITHRIX; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FAS RECEPTOR; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COMMON ANTIGENS; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; PILOT PROJECTS; PLAQUE, AMYLOID; WASTING DISEASE, CHRONIC;

EID: 84994609033     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160673     Document Type: Article

References (50)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O?Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer?s disease. Neurobiol Aging 21, 383-421.
2. Hardy J, Higgins G (1992) Alzheimer?s disease: The amyloid cascade hypothesis. Science 256, 184-185.
3. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer?s amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
4. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, Aimoto S, Elliott JI, Van Nostrand WE, Smith SO (2010) Structural conversion of neurotoxic amyloid-1-42 oligomers to fibrils. Nat Struct Mol Biol 17, 561-567.
5. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD (2001) Correlation between A-x-40-, A-x-42-, and A-x-43-containing amyloid plaques and cognitive decline. Arch Neurol 58, 2025-2032.
6. Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, Nishimura M, Iwata N, Van Broeckhoven C, Ihara Y, Saido TC (2011) Potent amyloidogenicity and pathogenicity of A-43. Nat Neurosci 14, 1023-1032.
7. Sondag CM, Dhawan G, Combs CK (2009) Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. J Neuroinflammation 6, 1.
8. Dhawan G, Floden A, Combs C (2012) Amyloid-oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging 33, 2247-2261.
9. Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, Bruno MA, Canneva F (2010) Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 7, 96-98.
10. Doens D, Fernández PL (2014) Microglia receptors and their implications in the response to amyloid-for Alzheimer?s disease pathogenesis. J Neuroinflammation 11, 48.
11. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, OhKW, Hong JT (2008) Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-Amyloid generation. J Neuroinflammation 5, 37.
12. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A (2002) Neuroinflammation in Alzheimer?s disease and prion disease. Glia 40, 232-239.
13. Hanzel CE, Pichet-Binette A, Pimentel LS, Iulita MF, Allard S, Ducatenzeiler A, Do Carmo S, Cuello AC (2014) Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer?s disease. Neurobiol Aging 35, 2249-2262.
14. Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol 29, 357-365.
15. Van Exel E, de Craen AJ, Remarque EJ, Gussekloo J, Houx P, Bootsma-van der Wiel A, Frölich M, Macfarlane PW, Blauw GJ, Westendorp RG (2003) Interaction of atherosclerosis and inflammation in elderly subjects with poor cognitive function. Neurology 61, 1695-1701.
16. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-A brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, 1-23.
17. Remarque E, Bollen EL, Weverling-Rijnsburger AW, Laterveer JC, Blauw GJ, Westendorp RG (2001) Patients with Alzheimer?s disease display a pro-inflammatory phenotype. Exp Gerontol 36, 171-177.
18. Tan J, Town T, Abdullah L, Wu Y, Placzek A, Small B, Kroeger J, Crawford F, Richards D, Mullan M (2002) CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer?s disease. J Neuroimmunol 132, 164-172.
19. Lombardi V, Garcia M (1999) Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer?s disease (AD) individuals. J Neuroimmunol 97, 163-171.
20. Griffin W, Sheng JG, Roberts GW, Mrak RE (1995) Interleukin-1 expression in different plaque types in Alzheimer?s disease: Significance in plaque evolution. J Neuropathol Exp Neurol 54, 276-281.
21. Logan AC, Khan KNM (1996) Case report: Clinical pathologic changes in two marmosets with wasting syndrome. Toxicol Pathol 24, 707-709.
22. Nakashima E, Okano Y, Niimi K, Takahashi E (2013) Detection of calprotectin and apoptotic activity in the colon of marmosets with chronic diarrhea. J Vet Med Sci 75, 1633-1636.
23. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ (1993) Evidence for the experimental transmission of cerebral beta-Amyloidosis to primates. Int J Exp Pathol 74, 441-454.
24. Ridley RM, Baker HF, Windle CP, Cummings RM (2006) Very long term studies of the seeding of beta-Amyloidosis in primates. J Neural Transm (Vienna) 113, 1243-1251.
25. Geula C, Nagykery N, Wu CK (2002) Amyloid-deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): Incidence and chemical composition. Acta Neuropathol 103, 48-58.
26. Mansfield K (2003) Marmoset models commonly used in biomedical research. Comp Med 53, 383-392.
27. Tardif SD, Mansfield KG, Ratnam R, Ross CN, Ziegler TE (2011) The marmoset as a model of aging and age-related diseases. ILAR J 52, 54-65.
28. Carrion R Jr, Patterson JL (2012) An animal model that reflects human disease: The common marmoset (Callithrix jacchus). Curr Opin Virol 2, 357-362.
29. Ross CN, Davis K, Dobek G, Tardif SD (2012) Aging phenotypes of common marmosets (Callithrix jacchus). J Aging Res 2012, 567143.
30. Finch CE, Austad SN (2012) Primate aging in the mammalian scheme: The puzzle of extreme variation in brain aging. Age 34, 1075-1091.
31. MacLean CJ, Baker HF, Ridley RM, Mori H (2000) Naturally occurring and experimentally induced beta-Amyloid deposits in the brains of marmosets (Callithrix jacchus). J Neural Transm 107, 799-814.
32. Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM (2011) Isolation of Low-n amyloid-protein oligomers from cultured cells, CSF, and brain. Meth Mol Biol 670, 33-44.
33. Jack CR Jr, Garwood M, Wengenack TM, Borowski B, Curran GL, Lin J, Adriany G, Gröhn OH, Grimm R, Poduslo JF (2004) In vivo visualization of Alzheimer?s amyloid plaques by MRI in transgenic mice without a contrast agent. Magn Reson Med 52, 1263-1271.
34. Uchihara T (2007) Silver diagnosis in neuropathology: Principles, practice and revised interpretation. Acta Neuropathol 113, 483-499.
35. Castellani R, Alexiev BA, Phillips D, Perry G, Smith MA (2007) Microscopic investigations in neurodegenerative diseases. In Modern Research and Educational Topics in Microscopy, Mendez-Vilas A, Diaz J, eds. Formatex, pp. 171-182.
36. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer?s pathological cascade. Lancet Neurol 9, 119-128.
37. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers Lifestyle (AIBL) Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer?s disease: A prospective cohort study. Lancet Neurol 12, 357-367.
38. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M (2005) Activation of microglia by aggregated beta-Amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 29, 381-393.
39. Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P (2003) Amyloid beta plaque-Associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol 105, 135-144.
40. Raji C, Becker J, Tsopelas N (2008) Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer?s disease with Pittsburgh Compound B. J Neurosci Meth 172, 277-282.
41. Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A (2014) Accelerated microglial pathology is associated with A-plaques in mouse models of Alzheimer?s disease. Aging Cell 13, 584-595.
42. Streit WJ (2006) Microglial senescence: Does the brain?s immune system have an expiration date? Trends Neurosci 29, 506-510.
43. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B (2004) How chronic inflammation can affect the brain and support the development of Alzheimer?s disease in old age: The role of microglia and astrocytes. Aging Cell 3, 169-176.
44. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease-A double-edged sword. Neuron 35, 419-432.
45. Solito E, Sastre M (2012) Microglia function in Alzheimer?s disease. Front Pharmacol 3, 14.
46. Schwartz M, Kipnis J (2004) A common vaccine for fighting neurodegenerative disorders: Recharging immunity for homeostasis. Trends Pharmacol Sci 25, 407-412.
47. McGeer PL, McGeer EG (1996) Anti-inflammatory drugs in the fight against Alzheimer?s disease. Ann N Y Acad Sci 777, 213-220.
48. In ?t Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, Stricker BH (1998) NSAIDs and incident Alzheimer?s disease. The Rotterdam Study. Neurobiol Aging 19, 607-611.
49. Launer L (2003) Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer?s disease. Drugs 63, 731-739.
50. C?oté S, Carmichael PH, Verreault R, Lindsay J, Lefebvre J, Laurin D (2012) Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer?s disease. Alzheimers Dement 8, 219-226.